Bajaj Healthcare Delivers Strong Q1 FY26 Results with 66% PAT Growth, 12.5% Revenue Uptick

Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its financial results for the quarter ended 30 June 2025. The company reported a 12.5% year-on-year increase in revenue from operations, reaching 1,488.4 Mn. Profit after tax (PAT) grew by 66% to 118.3 Mn, reflecting improved profitability and sharper execution across business segments. EBITDA remained steady at 253.9 million, with margins improving sequentially to 17.0% from 15.1%, despite input cost pressures. The API export business delivered standout growth of 68.4% YoY, and formulations saw 41.1% year-on-year growth. The company has strategically realigned its portfolio towards value-added exports and differentiated molecules to reinforce growth and profitability.